SCHEMBL280411

SCHEMBL280411

COC1CN(C(=O)c2ccc(C(=O)NN)s2)CC1O

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
TLR2 O60603 1/20 0.36
TLR1 Q15399 1/20 0.36
HPGD P15428 2/20 0.35
HRH3 Q9Y5N1 1/20 0.35
L3MBTL3 Q96JM7 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
SCN9A Q15858 1/20 0.34
MAPK1 P28482 1/20 0.34
F10 P00742 2/20 0.33
SLC18A3 Q16572 1/20 0.33
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
AOC3 Q16853 1/20 0.33
YEATS4 O95619 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL280183 0.92 ALDH1A1 (0.43) ALDH1A1KDM4EPOLBMAPTTLR2
SCHEMBL280182 0.87 ALDH1A1 (0.44) ALDH1A1KDM4EPOLBMAPTTLR2
SCHEMBL279900 0.82 HPGD (0.47) ALDH1A1KDM4EPOLBMAPTHPGD
SCHEMBL11984307 0.81 HPGD (0.57) ALDH1A1KDM4EPOLBMAPTHPGD
SCHEMBL14395887 0.80 SCN9A (0.35) ALDH1A1POLBTLR2TLR1HPGD
SCHEMBL11977473 0.79 YEATS4 (0.57) ALDH1A1POLBTLR2TLR1HPGD
SCHEMBL1587719 0.74 L3MBTL3 (0.47) ALDH1A1KDM4EPOLBMAPTHPGD
SCHEMBL279692 0.73 HPGD (0.51) ALDH1A1KDM4EPOLBMAPTHPGD
SCHEMBL1587143 0.72 HPGD (0.58) ALDH1A1KDM4EPOLBMAPTHPGD
SCHEMBL12313666 0.72 HPGD (0.62) ALDH1A1KDM4EPOLBMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL ALDH1A1 2047/4885KDM4E 4435/4885POLB 4352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.